Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035753 | 0.92 | ALDH1A1 (0.50) | HPGDCYP1A2CYP3A4CYP2C19POLB | |
| SCHEMBL6035446 | 0.86 | ALDH1A1 (0.46) | HPGDCYP1A2CYP3A4CYP2C19POLB | |
| SCHEMBL6035265 | 0.86 | TP53 (0.46) | HPGDCYP1A2CYP3A4CYP2C19POLB | |
| SCHEMBL5676551 | 0.84 | HPGD (0.55) | HPGDPOLBL3MBTL1RAB9ALMNA | |
| SCHEMBL6035371 | 0.84 | IDO1 (0.46) | HPGDRAB9ALMNAIDO1NPC1 | |
| SCHEMBL7800395 | 0.84 | HPGD (0.40) | HPGDCYP1A2CYP3A4CYP2C19POLB | |
| SCHEMBL6036049 | 0.83 | MAPT (0.43) | HPGDCYP3A4POLBALDH1A1TP53 | |
| SCHEMBL6036036 | 0.82 | CDK1 (0.55) | HPGDPOLBTP53L3MBTL1RAB9A | |
| SCHEMBL5392808 | 0.82 | IDO1 (0.47) | HPGDALDH1A1RAB9AIDO1NPC1 | |
| SCHEMBL6035710 | 0.82 | NUDT1 (0.48) | HPGDALDH1A1RAB9AIDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993437-B1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2006-11-08 | — | — | EP | claimed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | claimed |
| EP-1140291-B1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER LAMBERT CO (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1140062-B1 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-04-06 | — | — | EP | claimed |
| US-20040171632-A1 | Combination chemotherapy | GOWAN RICHARD CARLETON (US) | 2004-09-02 | — | — | US | claimed |
| US-6696440-B1 | ADMINISTERING MITOGEN ACTIVATED PROTEIN KINASE(MEK) INHIBITORS COMPRISING SECONDARY CARBOCYCLIC AMINES, AS ANTIASTHMATIC AGENTS | WARNER-LAMBERT COMPANY | 2004-02-24 | — | — | US | claimed |
| US-20030149015-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BARRETT STEPHEN DOUGLAS (US) | 2003-08-07 | — | — | US | claimed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | claimed |
| JP-2003504400-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0993437-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001421-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149015-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BCOR, BCL6, CBR1 | HPGD 2790/4885CYP1A2 796/4885CYP3A4 807/4885 |
| US-20040171632-A1 | Combination chemotherapy | BUB1B, BUB1, PLK1 | HPGD 2596/4885CYP1A2 2492/4885CYP3A4 3168/4885 |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | MMP8, SERPINB1, CXCR2 | HPGD 708/4885CYP1A2 3397/4885CYP3A4 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.